Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

BioCryst Pharmaceuticals Inc (NASDAQ:BCRXannounced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

  • The results showed sustained reductions in attack rates and improved quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to Orladeyo.
  • The analysis stratified all 21 patients by their initial reduction in HAE attack rate from baseline to Week 24 in three groups - Group A (<50 percent attack rate reduction; n=4), Group B (≥50 percent attack rate reduction; n=17), and Group C (≥70 percent attack rate reduction; n=14). 
  • Related: BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo.
  • A sustained reduction in HAE attack rates was observed from baseline to Week 96 across all three groups of patients. 
  • Group A had a mean decrease of 2.3 attacks/month, Group B had a mean decline of 2.5 attacks/month, and Group C had a mean reduction of 2.6 attacks/month.
  • At Week 96, median attack rates were 0.0 regardless of baseline attack rate.
  • Price Action: BCRX shares are down 2.77% at $16.24 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.